NorthWest Biotherapeutics Inc (NWBO)

[ae kusterer]

Roman516

Friday, July 08, 2022 1:39:52 AM

Re: FeMike post# 493358

Post#
493369
of 493429
FeMike,

"You have absolutely no idea how this manufacturing process works do you?"
Be more specific regarding your comment and accusations?

Based on your post 493322, it appears that you are the one that is clueless regarding the entire manufacturing capability process, and your lack of understand the manufacturing timeline to say the least.

post 493322, FeMike
"I don’t understand the logic on this estimate off the bat.
First, 15x multiple is very optimistic. I’ll give it to you but, optimistic.
Second, how are they treating 12.000 per year? They are currently at 600 capacity. Their anticipated max capacity with expansion is 12.000/year. If they were able to pull that trigger, that capacity wouldn’t be realized for several years. They have to build all of that out. “12000 almost immediately upon approval” is just not even close to accurate.

Third, why even include 100k+ patients per year in this chart? Market saturation is nowhere near that even as a remote potential. Only 12000 in the US of which you’re not likely getting more than 50%.

I get running the numbers, but come on."
=====================================================
My analysis for the current manufacturing capability process at Advent is based on my personal research, effort and detailed information gathering. It includes detailed research regarding the Flaskworks patents, math models, statistics, computer simulations, S-Curve analysis and multiple detailed spreadsheets that I have created over that last two years. I am new to this board, but I have been monitoring it for several years. As for may manufacturing expertise the fact is that I have over 45 years of advanced high level manufacturing processes, and my experience includes both the design and development of multiple products worth $$ billions in both profit and revenue. I have been involved with a number of Regulatory Approval process, JIT, 6-Sigma, ISO, CMMI and many others RA processes. I also have multiple advance degrees in engineering, hardware. software, firmware, product design and development, and a high-level math background in statistics, marketing and sales.

Regarding your comment,
"Yes, I absolutely understand how this manufacturing process works and have both the knowledge and experience to back it up"

All the best,

Roman516
pgsd

Friday, July 08, 2022 2:55:23 AM

Re: None

Post#
493374
of 493427
rj
@sharpie510

Ned Sharpless (Former Director @ NCI) mentions

#Glioblastoma & the new "Super-Charged Cancer Moonshot" to "end cancer as we know it".

????????????
The DCVax® Platform For All Solid Tumor Cancers
????????????

https://twitter.com/sharpie510/status/1545200547996659712Roman516

Friday, July 08, 2022 12:34:53 AM

Re: ae kusterer post# 493346

Post#
493365
of 493425
Kusterer,

Great post with detailed information. My research figures indicate that the percent of GBM cases are closer to the 4.5 persons per 100K people in the U.S. However, could be as high as 6% outside the US. Even at 4.5%, the world death rate for GBM cancer appears to be close to 355,000 per year, based on 2021 data, and an additional 1-2% population growth, (365,000) as of 2022. In either case, the death rate for GBM cases is a significant concern worthy to address and a need for a cure, and (DCVax-L) will help.
https://worldpopulationreview.com/countries/
https://www.cancer.net/cancer-types/brain-tumor/statistics/
https://braintumor.org/brain-tumor-information/brain-tumor-facts/

"Now depending upon which sources you use, it looks like the number of GBM cases run between 3 to 4.5 persons per 100k people here in the US."

"Quote:
The number of new cases of glioblastomas per year can thus be estimated at around 250,000 worldwide, with an over-incidence in the Caucasian populations and a slight increase anticipated in the years to come due to the aging of the population. It is also the most aggressive brain tumor with a median survival of fourteen to sixteen months and a five-year overall survival rate of less than 10% with the current standard of care. About 200,000 people die each year from a glioblastoma in the world, including nearly 15,000 in Europe and 9,000 in the United States.
https://www.gliocure.com/en/patients/glioblastoma/";;